INTRODUCTION
============

Gallbladder cancer (GBC) is the most common malignant tumor of the biliary tract. GBC is associated with a poor prognosis, with a 5-year overall survival (OS) rate of 18.5%, and only 20% of patients are eligible for resection at the time of diagnosis.[@b1-gnl-12-102] Palliative chemotherapy has shown survival benefits,[@b2-gnl-12-102] but the response rates are relatively low (17.1% to 36.6%).[@b3-gnl-12-102] The median survival time of patients with GBC is 4.6 to 11.7 months.[@b2-gnl-12-102],[@b3-gnl-12-102]

In biliary tract cancer, serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) have been associated with prognosis.[@b4-gnl-12-102] Changes in these tumor markers during treatment were reported as prognosticators in pancreatic cancer[@b5-gnl-12-102]--[@b8-gnl-12-102] and cholangiocarcinoma.[@b9-gnl-12-102] For GBC, serum CEA and CA 19-9 are useful diagnostic[@b10-gnl-12-102]--[@b13-gnl-12-102] and prognostic[@b12-gnl-12-102],[@b14-gnl-12-102]--[@b17-gnl-12-102] markers. However, previous studies employed spot measurements of CEA or CA 19-9, and studies evaluating the prognostic role of tumor marker kinetics in GBC have not been conducted.

The aim of the present study was to assess the prognostic values of serum CEA and CA 19-9 and their kinetics during palliative chemotherapy in patients with unresectable GBC.

MATERIALS AND METHODS
=====================

1. Patients and study design
----------------------------

A single-center retrospective study was conducted in patients with unresectable GBC, which was pathologically confirmed as adenocarcinoma between January 2005 and April 2015 at Seoul National University Hospital. Patients who underwent at least four cycles of palliative chemotherapy and who had baseline and postchemotherapy tumor marker records were included. Patients with other malignant tumors diagnosed previously, a history of systemic chemotherapy, or normal pre- and postchemotherapy tumor marker values were excluded ([Fig. 1](#f1-gnl-12-102){ref-type="fig"}). The final analysis set included 123 patients.

All patients were followed up until 30 November 2015, and observations were censored at the time of death or loss to follow-up.

2. Data collection
------------------

Patient characteristics such as age, sex, symptoms at admission, and comorbid disease status (Charlson comorbidity index score)[@b18-gnl-12-102] were obtained. Variables in tumor characteristics including tumor location (fundus, body, and neck) and distant metastasis were collected.

Serum CEA and CA 19-9 levels at baseline and postchemotherapy were evaluated. Baseline levels were measured within 3 days before chemotherapy initiation (CEA~pre~ and CA 19-9~pre~). Postchemotherapy levels were measured within 3 days after the end of the second cycle of chemotherapy (CEA~post~ and CA 19-9~post~). Serum CEA and CA 19-9 were measured using a commercially available immunoradiometric assays (CA 19-9: IZO TOP^®^, Institute of Isotopes Co., Ltd., Budapest, Hungary; CEA: RIAKEY^®^, Shinjin Medics Inc., Goyang, Korea). The initial total serum bilirubin levels and prothrombin times were also evaluated.

Data on progression-free survival (PFS) and OS were collected. Disease progression (PD) was assessed using abdominal computed tomography every two to four cycles of chemotherapy. PFS data was censored according to the date of loss to follow-up. The date of death was sourced from the records of the Korean Central Cancer Registry.

3. Statistical analyses
-----------------------

Tumor marker kinetics were defined as $\text{CEA}_{\text{change}} = \frac{\text{CEApost}}{\text{CEApre}}$ and $\text{CA }19 - 9_{\text{change}} = \frac{\text{CA }19 - 9\text{post}}{\text{CA }19 - 9\text{pre}}$. Combined tumor marker kinetics were defined as COMB~change~=CEA~change~×CA 19-9~change~. The median, and first and third quadrant values, of the kinetic parameters were calculated.

Receiver operating characteristic (ROC) curve analysis of CEA~change~, CA 19-9~change~, and COMB~change~ was performed to assess 3-month PFS and 1-year OS rates. The cutoff value for the highest sum of sensitivity and specificity was used for further analyses. Kaplan-Meier analyses were performed for survival evaluation. The log-rank test was used to assess the relationships between tumor marker kinetic parameters and PFS or OS.

Univariate analysis with the log-rank test was conducted to compare survival using the cutoff values of the tumor marker kinetic parameters. Factors associated with survival in the univariate analysis with a p-value \<0.10 were used in multivariate analysis. Cox regression analysis was performed to identify independent prognosticators.

Hazard ratios and 95% confidence intervals were calculated for each predictive factor. Two-sided p-values of \<0.05 were considered statistically significant. All statistical analyses were performed with IBM SPSS Statistics version 22.0 (IBM Corp., Armonk, NY, USA).

RESULTS
=======

1. Patient demographics
-----------------------

Baseline patient characteristics are listed in [Table 1](#t1-gnl-12-102){ref-type="table"}. The median age was 64 years (range, 25 to 85 years). Thirty patients had stage IIIb disease, all of which had unresectable disease due to extensive liver invasion or regional lymph node metastasis. The majority of patients underwent gemcitabine plus cisplatin chemotherapy (61.0%) with a mean duration of 4.8 (±3.0) cycles. Other chemotherapy regimens included TS-1 plus cisplatin (15.5%) with a mean duration of 5.2 (±3.1) cycles, gemcitabine plus oxaliplatin (13.8%) with a mean duration of 5.9 (±3.7) cycles, gemcitabine plus TS-1 (4.1%), infusional 5-fluorouracil, doxorubicin, and mitomycin-C (1.6%), capecitabine alone (1.6%), and TS-1 alone (2.4%). The median Charlson comorbidity index was 8 (range, 3--13). The median serum CEA and CA 19-9 levels were 3.9 mg/L (range, 0.5 to 1,350 mg/L) and 413 U/mL (range, 1 to 145,000 U/mL), respectively. The median interval between diagnosis and chemotherapy was 16 days (range, 0 to 123 days). The median PFS and OS were 3.9 and 8.1 months, respectively.

2. Prognostic value of CEA~change~, CA 19-9~change~, and COMB~change~
---------------------------------------------------------------------

In the ROC analysis, the areas-under-the-curve of the CEA~change~, CA 19-9~change~, and COMB~change~ for predicting 3-month PFS were 0.727, 0.750, and 0.734, whereas those for 1-year OS were 0.623, 0.742, and 0.720, respectively ([Fig. 2](#f2-gnl-12-102){ref-type="fig"}).

The relationships between tumor marker kinetics and survival are shown in [Table 2](#t2-gnl-12-102){ref-type="table"}. CA 19-9~change~ was significantly correlated with PFS and OS. However, CEA~change~ was significantly correlated with PFS and OS only at the cutoff value of 1.0. The relationship between COMB~change~ and PFS and OS was variable but significant at most values with the exception of a cutoff value of 2.0 for OS.

Survival curves according to tumor kinetic parameters using a cutoff value of 1.0 are shown in [Fig. 3](#f3-gnl-12-102){ref-type="fig"}. The median PFS was 5.9 and 2.3 months in patients with a CEA~change~ of \<1 and ≥1, respectively (p=0.002). The median OS was 11.4 and 6.2 months in those with a CEA~change~ of \<1 and ≥1, respectively (p=0.036). The median PFS was 5.6 and 2.2 months in patients with a CA 19-9~change~ of \<1 and ≥1, respectively (p\<0.001). The median OS was 9.6 and 6.6 months in patients with a CA 19-9~change~ of \<1 and ≥1, respectively (p=0.008). The median PFS was 5.3 and 2.1 months in those with a COMB~change~ of \<1 and ≥1 (p=0.002). The median OS was 8.9 and 6.2 months in those with a COMB~change~ of \<1 and ≥1, respectively (p=0.011).

CA 19-9~change~ was the most valuable prognostic marker. Kaplan-Meier analyses according to CA 19-9~change~ cutoff value of 0.4, 1.0, and 2.0 (which represent the first quadrant, median, and third quadrant) are shown in [Fig. 4](#f4-gnl-12-102){ref-type="fig"}. Patients with a CA 19-9~change~ \<0.4 had significantly better survival compared to those with greater changes. The linearity of the PFS and OS in were statistically significant (both p\<0.001). Because CA 19-9~change~ was the most valuable prognosticator, we used CA 19-9~change~ as a marker in further analyses.

3. CA 19-9~change~ as a predictor of response to chemotherapy
-------------------------------------------------------------

Responses after four-cycle (rather than 3-month due to the variety of chemotherapy regimen) of chemotherapy were assessed according to the modified Response Evaluation Criteria in Solid Tumors (version 1.1). Sixteen patients (13.0%) had a partial response, 41 (33.3%) had stable disease, and 66 (53.7%) showed PD. A high CA 19-9~change~ was correlated with PD (p=0.001), but a low CA 19-9~change~ was not associated with partial response (p=0.500). Three patients with a CA 19-9~change~ \>10.0 showed PD after four-cycle of chemotherapy, and 20 patients with CA 19-9~change~ \>3.0, 17 (85%) of whom underwent four-cycle of chemotherapy showed PD.

4. Prognostic value of CA 19-9~change~ associated with PFS
----------------------------------------------------------

The correlations of CA 19-9~change~ with other baseline variables were analyzed, but there were no significant correlations ([Table 3](#t3-gnl-12-102){ref-type="table"}). Univariate analysis revealed that male sex (p=0.095), a primary mass located in the gallbladder neck (p=0.076), positive distant metastasis (p=0.018), CEA ≥4.0 ng/mL at diagnosis (p=0.045), and CA 19-9~change~ ≥1.0 (p\<0.001) had a p-value of \<0.10 for PFS. However, CA 19-9~change~ ≥1.0 alone was an independent prognosticator of PFS (p=0.001) ([Table 4](#t4-gnl-12-102){ref-type="table"}).

5. Prognostic value of CA 19-9~change~ associated with OS
---------------------------------------------------------

Univariate analyses revealed that male sex (p=0.058), an Eastern Cooperative Oncology Group performance score of 2 (p=0.050), distant metastasis (p=0.072), CEA ≥4.0 ng/mL (p=0.001), CA 19-9 ≥400 U/mL (p=0.007), and CA 19-9~change~ ≥1.0 (p=0.008) had a p-value of \<0.10. Multivariate Cox regression analysis showed that baseline CEA ≥4.0 ng/mL, baseline CA 19-9 ≥400 U/mL, and CA 19-9~change~ ≥1.0 were independent prognosticators of OS (p=0.018, p=0.022, and p=0.020, respectively) ([Table 5](#t5-gnl-12-102){ref-type="table"}).

6. Effect of total serum bilirubin on CA 19-9 levels
----------------------------------------------------

The correlation between serum CA 19-9 and serum total bilirubin level, and that between CA 19-9~change~ and serum total bilirubin were not significant (p=0.155 and 0.845, respectively). We did a subgroup analysis which divided the subjects according to serum total bilirubin levels, and 29 out of 106 patients had a serum total bilirubin level \>3.0 mg/dL ([Table 6](#t6-gnl-12-102){ref-type="table"}). The median PFS was 4.0 and 2.7 months in patients with a CA 19-9~change~ of \<1 and ≥1, respectively (p=0.296). The median OS was 7.1 and 6.7 months in patients with a CA 19-9~change~ of \<1 and ≥1, respectively (p=0.955).

DISCUSSION
==========

In this retrospective study, we aimed to assess the prognostic value of serum tumor marker kinetics after chemotherapy in patients with unresectable GBC. The results revealed that tumor marker changes after first two cycles of chemotherapy were independent prognosticators of survival. Serum CEA, serum CA 19-9, or a combination of the two were valuable prognosticators; however, among them, CA 19-9 kinetics was the most valuable prognosticator of survival. In addition, the serum CA 19-9 level after two cycles of chemotherapy was a valuable predictor of PD after four cycles of chemotherapy. Therefore, we suggest that patients with \>10-fold increase in serum CA 19-9 after two cycles of chemotherapy should be considered as having PD, and patients with \>3-fold increase in serum CA 19-9 should be considered for early imaging studies.

Multivariate analyses in previous studies of patients with GBC that utilized specific cutoff values of spot serum CA 19-9 did not identify serum CA 19-9 as an independent prognosticator.[@b19-gnl-12-102]--[@b21-gnl-12-102] This could be explained by the wide variation in CA 19-9 secretion levels between GBC cases. Although the serum CA 19-9 levels vary between patients and may not represent tumor burden, the relative value of CA 19-9 in a single patient may be reflective of the tumor burden, regardless of the absolute CA 19-9 level. The present study showed that the relative change in CA 19-9 did not correlated with spot serum CA 19-9 measurements, and that the relative change was an independent prognosticator, similar to previous findings in pancreatic cancer[@b5-gnl-12-102]--[@b8-gnl-12-102] and cholangiocarcinoma.[@b9-gnl-12-102]

Yu *et al*.[@b14-gnl-12-102] focused on the change of serum CA 19-9 and CEA after resection of GBC. They showed that increased CA 19-9 and CEA after GBC resection were independent prognosticators of poor survival. Combined with postoperative pathology, which is the most important prognosticator, they classified postsurgical patients into different prognostic groups, which aided further decision making. Unlike patients with resectable GBC, patients with unresectable GBC undergo palliative chemotherapy and exhibit variable tumor responses, a valid assessment of such responses is critical in further decision making. The present study focused on the relationship between chemotherapy response and tumor marker changes, and identified criteria for early imaging follow-up or chemotherapy discontinuation based on these changes.

We excluded subjects with normal pre- and postchemotherapy tumor markers in this study and this may create some degree of selection bias. However, excluding such subjects does not facilitate any favorable tendency in the conclusion of this study. On the other hand, we could not conclude some issues regarding chemotherapy response due to the insufficient number of subjects. Despite tumor marker kinetics significantly correlated with progressive disease, we could not draw a conclusion correlating tumor marker kinetics with partial or complete response. Only 16 patients showed partial response to chemotherapy and there were no patients with complete response. Studies with a larger number of subjects are warranted to reach a conclusion.

High baseline serum total bilirubin is correlated with high baseline serum CA 19-9 level, and could therefore influence CA 19-9~change~.[@b22-gnl-12-102] There is no universal agreement on how to adjust the serum CA 19-9 level. Kim *et al*.[@b23-gnl-12-102] suggested a formula correcting the effect of serum total bilirubin on serum CA 19-9 level, which divides serum CA 19-9 level with serum total bilirubin level. However, the serum total bilirubin threshold 2.0 mg/dL makes this formula inadequate to this study due to the measurable nature of tumor marker changes. Instead, we did a subgroup analysis, and 29 of 106 patients had a serum total bilirubin level \>3.0 mg/dL ([Table 6](#t6-gnl-12-102){ref-type="table"}). High baseline serum bilirubin (\>3.0 mg/dL) tended to be associated with improved survival in patients with a lower CA 19-9~change~, although the association did not reach significance, most likely because of the small number of patients. Therefore, the influence of combined total bilirubin and serum CA 19-9 changes should be evaluated in further studies with a larger number of patients.

In conclusion, CA 19-9 kinetics is a valuable prognosticator of patient survival and treatment response during chemotherapy for unresectable GBC.
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![Receiver operating characteristic (ROC) curve analysis of tumor marker kinetics as predictors of survival. (A) Progression-free survival. (B) Overall survival.\
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![(A--F) Kaplan-Meier plot of progression-free and overall survival according to serum tumor marker changes after chemotherapy using a cutoff value of 1.0.\
CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; COMB, combination.](gnl-12-102f3){#f3-gnl-12-102}

![Progression-free (A) and overall survival (B) according to changes in carbohydrate antigen (CA) 19-9.](gnl-12-102f4){#f4-gnl-12-102}

###### 

Baseline Characteristics of Eligible Patients

  Characteristic                  Value
  ------------------------------- -------------------
  Sex                             
   Male                           62 (50.4)
   Female                         61 (49.6)
  Age, yr                         
   ≥65                            57 (46.3)
   \<65                           66 (53.7)
  Drinking history                
   Yes                            31 (25.2)
   No                             92 (74.8)
  Smoking history                 
   Yes                            27 (22.0)
   No                             96 (78.0)
  Symptoms                        
   Yes                            113 (91.9)
   No                             10 (8.1)
  CCI (cancer score subtracted)   
   ≥4.0                           46 (37.4)
   \<4.0                          77 (62.6)
  Total bilirubin, mg/dL          
   ≥3.0                           32 (26.0)
   \<3.0                          91 (74.0)
  CEA, ng/mL                      
   ≥4.0                           66 (46.3)
   \<4.0                          57 (53.7)
  CA 19-9, U/mL                   
   ≥400                           68 (55.3)
   \<400                          55 (44.7)
  Performance status (ECOG)       
   0 or 1                         103 (82.1)
   2                              22 (17.9)
  Location                        
   Fundus and body                95 (77.2)
   Neck                           28 (22.8)
  Metastasis                      
   Yes                            78 (63.4)
   No                             45 (36.6)
  Stage                           
   IIIb                           30 (24.4)
   IVa                            15 (12.2)
   IVb                            78 (63.4)
  Biliary drainage                
   Yes                            51 (41.5)
   No                             7 (58.5)
  Chemotherapy                    
   Gemcitabine-based              99 (80.5)
   Others                         24 (19.5)
  Concurrent radiotherapy         5 (4.1)
  CEA~change~ (n=68)              1.41 (0.06--10.0)
  CA19-9~change~ (n=106)          1.00 (0.01--46.9)
  COMB~change~ (n=51)             1.19 (0.01--186)

Data are presented as number (%) or median (range).

CCI, Charlson comorbidity index; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; ECOG, Eastern Cooperative Oncology Group; COMB, combination.

###### 

Sensitivity and Specificity for Predicting PFS and OS According to Serum Tumor Marker Changes after Chemotherapy

                    PFS                                                   OS                                                                                                                                                                                                                        
  ----------------- ----------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  Cutoff 0.5                                                                                                                                                                                                                                                                                        
   Sensitivity, %   91.7[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       84.2[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       82.8[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       82.8[†](#tfn6-gnl-12-102){ref-type="table-fn"}         82.8[†](#tfn6-gnl-12-102){ref-type="table-fn"}         82.8[†](#tfn6-gnl-12-102){ref-type="table-fn"}
   Specificity, %   31.2[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       51.0[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       50.0[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       50.0[†](#tfn6-gnl-12-102){ref-type="table-fn"}         50.0[†](#tfn6-gnl-12-102){ref-type="table-fn"}         50.0[†](#tfn6-gnl-12-102){ref-type="table-fn"}
    \<0.5           5.93±1.50[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   6.00±1.11[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   5.93±1.19[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   10.20±2.65[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   11.40±1.19[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   11.40±1.49[‡](#tfn7-gnl-12-102){ref-type="table-fn"}
    ≥0.5            2.57±0.63[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   2.47±0.29[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   2.10±0.41[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   6.60±0.39[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    6.80±0.23[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    6.00±0.61[‡](#tfn7-gnl-12-102){ref-type="table-fn"}
   p-value          0.067                                                 \<0.001                                               0.009                                                 0.258                                                  0.001                                                  0.011
  Cutoff 1.0                                                                                                                                                                                                                                                                                        
   Sensitivity, %   83.3[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       68.4[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       72.4[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       72.4[†](#tfn6-gnl-12-102){ref-type="table-fn"}         72.4[†](#tfn6-gnl-12-102){ref-type="table-fn"}         72.4[†](#tfn6-gnl-12-102){ref-type="table-fn"}
   Specificity, %   59.4[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       69.4[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       68.2[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       68.2[†](#tfn6-gnl-12-102){ref-type="table-fn"}         68.2[†](#tfn6-gnl-12-102){ref-type="table-fn"}         68.2[†](#tfn6-gnl-12-102){ref-type="table-fn"}
    \<1.0           5.87±0.36[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   5.60±0.79[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   5.30±0.78[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   11.40±0.80[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   9.60±1.12[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    8.93±2.16[‡](#tfn7-gnl-12-102){ref-type="table-fn"}
    ≥1.0            2.31±0.36[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   2.17±0.27[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   2.10±0.23[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   6.17±0.50[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    6.63±0.43[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    6.17±0.52[‡](#tfn7-gnl-12-102){ref-type="table-fn"}
   p-value          0.002                                                 \<0.001                                               0.002                                                 0.036                                                  0.008                                                  0.011
  Cutoff 2.0                                                                                                                                                                                                                                                                                        
   Sensitivity, %   27.8[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       45.6[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       55.2[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       55.2[†](#tfn6-gnl-12-102){ref-type="table-fn"}         55.2[†](#tfn6-gnl-12-102){ref-type="table-fn"}         55.2[†](#tfn6-gnl-12-102){ref-type="table-fn"}
   Specificity, %   85.4[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       85.7[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       72.7[\*](#tfn5-gnl-12-102){ref-type="table-fn"}       72.7[†](#tfn6-gnl-12-102){ref-type="table-fn"}         72.7[†](#tfn6-gnl-12-102){ref-type="table-fn"}         72.7[†](#tfn6-gnl-12-102){ref-type="table-fn"}
    \<2.0           4.27±0.97[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   4.40±0.71[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   4.37±0.54[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   7.47±0.80[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    8.80±0.99[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    7.87±1.11[‡](#tfn7-gnl-12-102){ref-type="table-fn"}
    ≥2.0            2.47±0.53[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   2.10±0.40[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   2.17±0.49[‡](#tfn7-gnl-12-102){ref-type="table-fn"}   6.57±0.25[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    6.53±0.54[‡](#tfn7-gnl-12-102){ref-type="table-fn"}    6.53±0.47[‡](#tfn7-gnl-12-102){ref-type="table-fn"}
   p-value          0.397                                                 0.001                                                 0.039                                                 0.692                                                  0.021                                                  0.173

Data are presented as mean±SD.

PFS, progression-free survival; OS, overall survival; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; COMB, combination.

Sensitivity plus specificity for 3-month PFS;

Sensitivity plus specificity for 1-year OS;

Survival in months.

###### 

Correlations between Changes in CA 19-9 and Other Variables

                                  CA 19-9   p-value   
  ------------------------------- --------- --------- -------
  Sex                                                 
   Male                           26        30        
   Female                         27        23        0.560
  Age, yr                                             
   ≥65                            27        23        
   \<65                           26        30        0.560
  Drinking                                            
   Yes                            16        12        
   No                             37        41        0.509
  Smoking                                             
   Yes                            11        13        
   No                             42        40        0.817
  CCI (cancer subtracted score)                       
   ≥4.0                           21        20        
   \<4.0                          32        33        1.000
  Symptoms                                            
   Yes                            47        50        
   No                             6         3         0.488
  Location                                            
   Fundus and body                35        45        
   Neck                           18        8         0.041
  Distant metastasis                                  
   Yes                            31        39        
   No                             22        14        0.151
  Biliary drainage                                    
   Yes                            25        19        
   No                             28        34        0.324
  CEA, ng/mL                                          
   ≥4.0                           25        27        
   \<4.0                          28        26        0.846
  CA 19-9, U/mL                                       
   ≥400                           37        27        
   \<400                          16        26        0.073

CA 19-9, carbohydrate antigen 19-9; CCI, Charlson comorbidity index; CEA, carcinoembryonic antigen.

###### 

Prognosticators of PFS in Patients with Unresectable Gallbladder Cancer

                                                  Univariate   Multivariate                                 
  ----------------------------------------------- ------------ -------------- --------- ------ ------------ -------
  Sex                                                                                                       
   Male                                           62           2.7                                          
   Female                                         61           4.8            0.095     0.81   0.53--1.23   0.317
  Age, yr                                                                                                   
   ≥65                                            57           3.9                                          
   \<65                                           66           3.9            0.918                         
  Drinking                                                                                                  
   Yes                                            31           4.0                                          
   No                                             92           3.7            0.315                         
  Smoking                                                                                                   
   Yes                                            27           3.9                                          
   No                                             96           4.0            0.839                         
  Symptom                                                                                                   
   Yes                                            113          3.9                                          
   No                                             10           2.6            0.826                         
  Performance status (ECOG)                                                                                 
   0 or 1                                         101          4.0                                          
   2                                              22           3.2            0.505                         
  Location                                                                                                  
   Fundus and body                                95           3.4                                          
   Neck                                           28           4.5            0.076     0.79   0.46--1.38   0.410
  Distant metastasis                                                                                        
   Yes                                            78           2.7                                          
   No                                             45           5.7            0.018     1.45   0.92--2.29   0.115
  Biliary drainage                                                                                          
   Yes                                            51           3.4                                          
   No                                             72           4.8            0.171                         
  Total bilirubin, mg/dL                                                                                    
   ≥3.0                                           32           3.4                                          
   \<3.0                                          91           4.3            0.336                         
  CEA, ng/mL                                                                                                
   ≥4.0                                           66           3.2                                          
   \<4.0                                          57           4.4            0.066     1.44   0.91--2.29   0.112
  CA 19-9, U/mL                                                                                             
   ≥400                                           68           3.9                                          
   \<400                                          55           3.9            0.328                         
  Chemotherapy                                                                                              
   GP                                             75           4.0                                          
   Others                                         48           3.4            0.851                         
  Interval between diagnosis and treatment, day                                                             
   ≤15                                            59           4.0                                          
   \>15                                           64           3.9            0.433                         
  CA 19-9~change~                                                                                           
   ≥1.0                                           53           5.6                                          
   \<1.0                                          53           2.2            \<0.001   2.20   1.39--3.47   0.001

PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; GP, gemcitabine plus cisplatin.

###### 

Prognosticators of OS in Patients with Unresectable Gallbladder Cancer

                              Univariate   Multivariate                               
  --------------------------- ------------ -------------- ------- ------ ------------ -------
  Sex                                                                                 
   Male                       62           7.0                                        
   Female                     61           8.8            0.058   0.81   0.53--1.23   0.320
  Age, yr                                                                             
   ≥65                        57           6.9                                        
   \<65                       66           9.5            0.130                       
  Drinking                                                                            
   Yes                        31           7.5                                        
   No                         92           8.1            0.473                       
  Smoking                                                                             
   Yes                        27           8.3                                        
   No                         96           7.8            0.419                       
  Symptoms                                                                            
   Yes                        113          7.9                                        
   No                         10           8.9            0.274                       
  Performance status (ECOG)                                                           
   0 or 1                     101          8.3                                        
   2                          22           6.6            0.050   1.15   0.69--1.93   0.592
  Location                                                                            
   Fundus and body            95           7.8                                        
   Neck                       28           9.5            0.104                       
  Distant metastasis                                                                  
   Yes                        78           6.8                                        
   No                         45           9.6            0.072   1.35   0.87--2.11   0.186
  Biliary drainage                                                                    
   Yes                        51           7.0                                        
   No                         72           8.3            0.669                       
  Total bilirubin, mg/dL                                                              
   ≥3.0                       32           7.0                                        
   \<3.0                      91           8.1            0.763                       
  CEA, ng/mL                                                                          
   ≥4.0                       66           6.8                                        
   \<4.0                      57           9.6            0.001   1.76   1.10--2.80   0.018
  CA 19-9, U/mL                                                                       
   ≥400                       68           7.0                                        
   \<400                      55           9.6            0.007   1.74   1.08--2.80   0.023
  Chemotherapy                                                                        
   GP                         75           7.8                                        
   Others                     48           8.3            0.250                       
  CA 19-9~change~                                                                     
   ≥1.0                       53           6.6                                        
   \<1.0                      53           9.6            0.008   1.67   1.08--2.58   0.020

OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; GP, gemcitabine plus cisplatin.

###### 

Survival Analysis of High- and Low-Serum Bilirubin Subgroups

                    Bilirubin ≥3 mg/dL   Bilirubin \<3 mg/dL                        
  ----------------- -------------------- --------------------- ------- ------ ----- ---------
  PFS, median, mo   4                    2.7                   0.296   5.9    2.2   \<0.001
  OS, median, mo    7.1                  6.7                   0.955   10.2   6.6   \<0.001

CA 19-9, carbohydrate antigen 19-9; PFS, progression-free survival; OS, overall survival.
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